Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled, crossover phase II study of AXS-12 in patients with narcolepsy

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, crossover phase II study of AXS-12 in patients with narcolepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Reboxetine (Primary)
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Acronyms CONCERT
  • Most Recent Events

    • 30 Jan 2019 According to an Axsome Therapeutics media release, topline results from this trial are expected in the second quarter of 2019.
    • 30 Jan 2019 Status changed from planning to recruiting, according to an Axsome Therapeutics media release.
    • 27 Dec 2018 According to an Axsome Therapeutics media release, the company anticipates initiation of this study in January 2019, with topline results in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top